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RESUMEN
Objetivos: Sintetizar derivados triesterificados de la uridina y evaluar su citotóxicidad sobre una línea 
celular de cáncer de mama.
Métodos: Se prepararon derivados triesterificados de la uridina mediante la esterificación de Steglich 
para los ácidos grasos y aromáticos, y con anhídrido acético. Además se preparó el derivado acetonido 
mediante catálisis ácida. Los compuestos se caracterizaron por espectroscopia de RMN (RMN 1H y RMN 
13C), y espectrometría de masas. Los derivados se evaluaron sobre líneas celulares de tumor de ovario de 
hámster chino (CHO) y de cáncer de mamá (MCF-7).
Resultados: Se obtuvieron cinco derivados triesterificados de la uridina, uno con ácido acético, tres con 
ácidos grasos (ácido mirístico, ácido esteárico y ácido oleico) y uno con ácido aromático. Los derivados 
de uridina per-acetilada y acetonido se obtuvieron con rendimientos altos, sin embargo los derivados 
con ácidos grasos y aromático, se obtuvieron con rendimientos moderados y bajo, respectivamente. El 
acetonido y los compuestos 2 y 3, exhibieron inhibición significativa de la viabilidad celular sobre ambas 
líneas a la concentración más alta evaluada.
Conclusiones: El método de esterificación con agentes de acoplamiento utilizado, permitió obtener de-
rivados triesterificados de la uridina con ácidos grasos y aromáticos. No se observó actividad citotóxica 
significativa (p<0,05) para la uridina y sus derivados.
Palabras claves: actividad citotóxica; cáncer de mama; derivados de uridina; nucleósidos; síntesis de 
ésteres
SUMMARY
Aims: Synthesize tri-acyl ester derivatives of uridine, and evaluate its cytotoxicity against 
breast cancer cells line.
Methods: The tri-esterified uridine derivatives were obtained through Steglich esterification 
reaction by fatty and aromatic acids, and with acetic anhydride. An acetonide derivative 
from uridine was prepared with acid catalysis. Compounds were characterized by NMR 
spectroscopy (1H NMR and 13C NMR), and mass spectrometry. Derivatives were assessed in 
chinese hamster ovary (CHO-K1) and human breast cancer (MCF-7) cell lines.
Results: Five tri-acyl ester derivatives of uridine were obtained one acetic acid, three fatty 
acids (myristic acid, stearic acid and oleic acid) with an aromatic acid. The uridine per-acety-
lated and uridine acetonide were obtained in high yields, however, the tri-acyl ester deriva-
tives of uridine with fatty and aromatic acids were obtained in moderate and low yields, re-
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spectively. The acetonide and compounds 2 and 3 exhibited 
a cell viability inhibition significant on both cell lines to the 
higher concentration.
Conclusions: Esterification method with coupling agents 
allowed obtained tri-acyl ester uridine derivatives with ali-
phatic and aromatic acids. However, significant cytotoxic 
activity (p<0.05) for uridine and its derivatives was not ob-
served.
Key words: breast cancer; cytotoxic activity; esters synthesis; nu-
cleosides; uridine derivatives
INTRODUCTION
Breast cancer is among the ten cancer types with higher 
world mortality1,2. Nucleoside analog drugs are widely 
used in cancer chemotherapy against soft tumors (leukemia 
and lynphome non-Hodking) and solid tumors (lung, liver, 
breast,)3,4. They show multiple action mechanisms: Inhibi-
tion of DNA synthesis, transcription and replication, DNA 
demethylation, destabilization of mitochondrial membrane 
and, activation of factors and apoptosis routes4-6. However, 
the anticancer nucleoside drugs presents pharmacokinetic 
(low selectivity by cancer cell and great chemical lability, 
and biological, among others) and pharmacodynamic (low 
incorporation in cells and intracellular inactivation and 
degradation by nucleoside deaminase and ectonucleotidase 
enzymes, respectively, among others) disadvantages3,7-9.
Investigations found that uridine (a natural and necessary 
nucleoside) and some her phosphorylated and glycosylat-
ed derivatives, exhibit cellular regulatory functions: mem-
brane synthesis modulation, glycosyl-transferase cofactors 
activation/deactivation, purinergic receptor agonists P2Xn 
and P2Ym, UTP does ATP functions, when, low amounts 
of ATP is available, and some uridine derivatives show 
inhibition of DNA polymerases. Furthermore, the uridine 
and some biological derivatives behave as antimetabolites, 
when their extracellular concentrations is higher than those 
physiological level2,5,10-12.
Investigations have focused on the synthesis of uridine 
derivatives with best physical-chemical and biological 
properties, such as: synthesis of glycosilated derivatives 
of uridine with potential glycosil-transferase inhibitory ac-
tivity11,12, Synthesis and citotoxic activity evaluation of uri-
dine derivatives with aliphatic groups, 3’-C-ethynyluridine 
and uridine acetonide conjugates with triterpenoids, in 
breast cancer13,14, the triacetil-ester derivative of uridine has 
shown modulators effects in patients on the fluorouracil 
toxicity, exhibited when was used in high doses or longer 
treatments15.
Owing to the disadvantages and side effects by nucleosides 
previously displayed, it was proposed, synthesize uridine 
derivatives of ester type with different aliphatic and aro-
matic acids, and cell viability evaluation in breast cancer 
cell.
MATERIALS AND METHODS
Chemical
Reagent grade solvents: hexane and ethyl acetate 99% pu-
rity (Honeywell), dichloromethane, chloroform, acetone 
and methanol, N,N-dimethylformamide (DMF) 99% pu-
rity (Merck), and triethylamine (TEA) 99.9% (J.T. Baker). 
Uridine 99% (Alfaesar), acetic anhydride 99% (Merck), cou-
pling agent: N,N´-diciclohexil-carbodiimide (DCC) 99%, 
and nucleophilic catalyst: 4-N,N-dimethylamino-pyridine 
(DMAP) 99% (Alfaesar), fatty acids (myristic, stearic and 
oleic acids) 99% (Merck), and aromatic acids (o-N-acetylan-
thranilic, p-nitrobenzoic and 3,5-dinitrobenzoic acids) 99% 
(Merck). Chromatography Column (silica gel 60N) with 
gradient: hexane/ethyl acetate and ethyl acetate/acetone 
mixes, and preparative Thin-Layer Chromatography with 
ethyl acetate/acetone mix as eluent. All compounds were 
characterized by nuclear magnetic resonance spectroscopy 
(1H-NMR, 13C-NMR, COSY H-H, HSQC and HMBC) on a 
Bruker NMR spectrometer (300 MHz, software Bruker Top-
Spin 3.1). Tetramethylsilane (TMS) was used as an internal 
standard, and deuterated chloroform (CDCl3) and deuter-
ated dimethyl sulfoxide (DMSO-d6) 99% deuterium purity 
(Merck) were used as solvents. Mass spectra analyses were 
performed on an Agilent 6100 Series-LC/MS Equipment 
(electrospray ionization (ESI) and single quadrupole ana-
lyzer in positive mode) and a Agilent 6300-LC/MS Equip-
ment (electrospray ionization (ESI) and Ion-Trap analyzer 
in positive mode) by direct injection method.
3’,4’,6’-O-triacetyl-uridine (1)
DMAP (5 mol-%) was aggregated to uridine (300 mg) so-
lution in acetic anhydride/DMF/TEA (1:1:1) mixture. The 
reaction mixture was stirred at room temperature for 6 
hours (for chemical reaction see figure 1) 16. The product 
was isolated as yellow solid (quantitative yield), Melting 
point: 127-128 °C. 1H NMR and 13C NMR data are in table 
1. ESI-MS (positive mode) m/z: Calculated for C15H18N2O9: 
370.3114; found, 393.1 [M+Na]+.
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Figure 1. Reaction scheme for the uridine tri-esterified derivative formation by Steglich 
esterification method and with anhydride acid.
General procedure for the synthesis of tri-acyl ester de-
rivatives
The esterification reaction for all three hydroxyl groups of 
uridine with fatty and aromatic acids was performed by 
Steglich esterification. DCC (1.5 equivalents respect to or-
ganic acid) was aggregated to organic acid (3.2 equivalents 
respect to uridine) solution in Chloroformo/DMF/TEA 
(1:2:1) mixture, after DMAP (5 mol-%) and uridine (300 
mg) was added14,17,18. The reaction mixture was stirred at 
room temperature for 8 to 10 days (for chemical reaction 
see figure 1).
3’,4’,6’-O-tris-(o-N-Acetyl)-benzoyl-uridine (3’,4’,6’-O-tris-
(O-N-acetyl)-anthraniloyl-uridine) (2)
The product was isolated as yellow solid (10-day reaction 
time, 25% yield). 1H NMR and 13C NMR data are in table 
1. ESI-MS (positive mode) m/z: Calculated for C36H33N5O12: 
727.6735; found, 750.5 [M+Na]+.
3’,4’,6’-O-trimyristoyl-uridine (3)
The product was isolated as white solid (8-day reaction 
time, 20% yield), Melting point: 63-64 °C. 1H NMR and 13C 
NMR data are in table 1. ESI-MS (positive mode) m/z: Cal-
culated for C51H90N2O9: 875.2683; found, 898.6 [M+Na]
+.
3’,4’,6’-tristearoyl-uridine (4)
The product was isolated as white solid (8-day reaction 
time, 20% yield), Melting point: 68-69 °C. 1H NMR and 13C 
NMR data are in table 1. ESI-MS (positive mode) m/z: Cal-
culated for C63H114N2O9: 1043.5872; found, 1066.9 [M+Na]
+ 
and 1044.9 [M+H]+.
3’,4’,6’-trioleoyl-uridine (5)
The product was isolated as yellow foam (9-day reaction 
time, 15% yield). 1H NMR and 13C NMR data are in table 
1. ESI-MS (positive mode) m/z: Calculated for C63H108N2O9: 
1037.5396; found, 1059.9 [M+Na]+.
3’,4’- uridine acetonide (6)
Uridine (300 mg) was dissolved in dry acetone, after sulfu-
ric acid was added to solution (30 uL at 98%). The reaction 
mixture was stirred at room temperature for 3 hours14,16. 
The product was isolated as yellow solid (90% yield). 1H 
NMR and 13C NMR data are in table 1. ESI-MS (positive 
mode) m/z: Calculated for C12H16N2O6: 284.2652; found, 
307.1 [M+Na]+.
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Table 1. 1H-NMR and 13C-NMR signals of acetonide, C1, and C2 compounds
Mass
C6
(DMSO d6)
C1
(DMSO d6)
C2
(DMSO d6)
Position
δ H (ppm), mult 
(Integ), J(Hz)
δ C (ppm), 
Integ
δ H (ppm), mult 
(Integ), J(Hz)
δ C (ppm), 
Integ
δ H (ppm), mult 
(Integ); J(Hz)
δ C (ppm); 
(Integ)
9» 2.13; s (9H) 25.12; (3C)
8» 169.54; (3C)
7»
8.46; dd (3H);
8.3 and 1,3
131.47; (3C)
6» 7.12; m (3H) 122.90; (3C)
5» 7.55; m (3H) 134.27; (3C)
4»
7.97; dd (3H);
7.9 and 1.5
120.13; (3C)
3» 1.48; s (3H) 27.49; (1C) 142.07; (4C)
2» 1.26; s (3H) 25.57; (1C)
2.68; d (6H) and 
2.71; s (3H)
21.29, (3C) 117.01; (3C)
1» 113.43; (1C)
170.25; (2C) 
170.95; (1C)
168.15; (3C)
6’ 3.57; m (2H) 61.67; (1C) 4.88; m (3H) 63.74; (1C) 4.27; m (3H) 63.24; (1C)
5’ 4.06; q (1H); 4,2 84.13; (1C) 4.88 79.75; (1C) 4.27 79.50; (2C)
4’
4.74; dd (1H); 6.3 
and 3.5
79.61; (1C) 5.96; m (1H) 70.47; (1C) 5.34; m (1H) 74.34; (1C)
3’
4.89; dd (1H); 6.3 
and 2.6
80.92; (1C) 6.08; m (1H) 72.61; (1C) 5.45; m (1H) 79.50
2’ 5.82; d (1H); 2.6 91.58; (1C) 6.51; d (1H); 5.1 89.02; (1C) 5.89; d (1H); 5.2 88.42; (1C)
6 7.79; d (1H); 8.1 142.47; (1C) 8.33; d (1H); 8.1 144.44; (1C) 7.72; d (1H); 8.1 142.07 (1C)
5 5.63; d (1H); 8.0 102.19; (1C) 6.35; d (1H); 8.0 103.29; (1C) 5.72; d (1H); 7.9 102.65; (1C)
4 163.67; (1C) 164.01; (1C) 163.88; (1C)
2 150.79; (1C) 151.26; (1C) 150.58; (1C)
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Table 1 (Cont.). 1H-NMR and 13C-NMR signals of C3, C4 and C5 compounds
Mass
C3
(CDCl3)
C4
(CDCl3)
C5
(CDCl3)
Position
δ H (ppm), mult 
(Integ); J(Hz)
δ C (ppm); 
(Integ)
δ H (ppm), mult 
(Integ); J(Hz)
δ C (ppm); 
(Integ)
δ H (ppm); 
mult (Integ); 
J(Hz)
δ C (ppm); 
(Integ)
18’’ 0.87, t (9H), 6.5 13.73; (3C) 0.85; t (9H) 14.43; t (3C)
17’’ 1.25 22.31; (3C) 1.25 22.43; (3C)
16’’ 1.25 31.64; (3C) 1.25 31.70; (3C)
15’’ 1.25; m (84 H) 29.35 1.25; m (60H) 29.16
14» 0.92; t (9H), 6.6 14.11 (3C) 1.25 29.35 1.25 29.16
13» 1.32 22.69 (3C) 1.25; m (84 H) 29.35; (36C), 1.25; m (60H) 29.16; (9C)
12» 1.32 32.78 (3C) 1.25 29.35 1.25 29.56
8’’ and 11’’ 1.32 29.46 1.25 29.35 1.96; m (12H) 26.86; (6C)
9’’ and 10’’ 1.32; m (48 H) 29.46 1.25 29.35 5.31; dd (6H) 130.18; (6C)
7» 1.32 29.46 1.25 29.35 1.25 29.56; (6C)
4», 5» and 
6»
1.32 29.46 (24C) 1.25 29.35 1.25 28.75; (9C)
3’’ 1.70; m (6H)
24.72, (2C)
25.11 (1C)
1.56; m (6H) 24.54, (3C) 1.49; m (6H) 24.77; (3C)
2’’ 2.40; dt (4H)
33.84 (1C)
35.98 (2C)
2.32; m (6H) 33.87, (3C)
2.09; t (2H) 
2.27; t (4H)
33.75; (3C)
1’’
172.46; (1C)
174.11 (2C)
172.17, (2C) 
172.68, (1C)
173.59; (3C)
6’ 4.38 62.61; (1C) 4.35 63.19; (1C) 4.25
5’ 4.38; m (3H) 80.18; (1C) 4.35; (3H) 80.14; (1C) 4.25; m (3H)
4’ 5.36 70.05; (1C) 5.35; m (2H) 70.21; (1C) 5.31; m (1H)
3’ 5.36; d (2H); 3.5 72.61; (1C) 5.35; m (2H) 72.61; (1C) 5.45; t (1H)
2’ 6.08; d (1H), 87.17; (1C) 6.05; d (1H), 4.6 87.44; (1C) 5.87; d (1H)
6 7.45; d (1H); 8.2 139.12; (1C) 7.49; d (1H), 8.2 139.71; (1C) 7.69; d (1H)
5 5.80; d (1H), 8.2 103.16 (1C) 5.80; d (1H), 8.1 103.19; (1C) 5.69; d (1H)
4 157.18, (1C) 163.96; (1C)
2 149.87; (1C) 150.32 (1C)
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Viability assay
CHO-K1 cell line (Chinese Hamster Ovary, ATCC N° 
CCL61) and MCF-7 (human breast adenocarcinoma, 
ATCC N° HTB22), Ham F12 (Sigma) and DMEM (Sigma) 
culture medium, fetal bovine serum (FBS, Gibco, Brazil), 
penicillin 100 U/ml-streptomycin 100 µg/mL (Gibco) 
and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide,thiazolyl blue) (MTT, Sigma). Solvents: DMSO 
reagent grade 99,9% purity (Sigma) and 2-propanol rea-
gent grade 98% purity (J. T. Baker). Absorbance was read 
in Multiskan FC Microplate Photometer–ThermoScientific 
spectrophotometer.
Cell culture
CHO-K1 and MCF-7 cell lines in exponential phase were 
cultured in F-12 or DMEM medium were supplemented 
with 5% fetal bovine serum (FBS), penicillin 100 U/mL and 
streptomycin 100 µg/mL. The cultures were incubated at 
37°C during 48 hours. MCF-7 cell line was incubated in wet 
atmosphere with 5% CO2.
MTT assay
MCF-7 and CHO-K1 cells were seeded in 96 well plates 
with a cell density 5x103 and 6x103 cells per well respective-
ly, in DMEM or F-12 medium were supplemented with 5% 
FBS. The cultures were treated with concentrations of 1, 10 
and 100 µM of uridine or derivatives, were incubated for 
48 hours at 37°C for 48 hours. Later, 10 µL of MTT (5 mg/
mL, Sigma) were added, and the plates were incubated in 
darkness at 37ºC for 4 hours. After 100 µL of acidified iso-
propanol were added to plates, the cultures were agitated 
at room temperature for 1 hour. Absorbance was measured 
at 570 nm and cell viability percentage was calculated in 
three replicas of each treatment. Results were expressed 
with mean and standard deviation (X±SD) in at least two 
experiments. Statistical analysis was performed with two-
way ANOVA, Bonferroni test with p<0.05 with GraphPad 
Prism Version 5.0 Software.
RESULTS
Chemical
The Steglich esterification does not require of heating or an 
aggressive medium (acidic or basic), therefore, it is ideal 
method to work substrates highly acid labile or thermo-la-
bile as uridine. This method allowed the esterification of all 
three hydroxyl groups of uridine, with conversions 55-60% 
with fatty acids and about 50% for aromatic acid, but the 
tri-acyl ester derivatives of uridine were obtained in lower 
yields 15-25%.
The tri-acyl ester derivatives were identified by compari-
son of 1H-NMR, 13C-NMR, 1H-1H COSY, HSQC and HMBC 
data of uridine and uridine acetonide. 1H-NMR and 13C-
NMR signals for ribofuranose ring protons from deriva-
tives, were deviated significantly of the substrate (uridine) 
and acetonide derivative (see table 1). The NMR data are 
agreement with the proposed structures.
Viability assay
Figure 2, shows the results of cell viability obtained by MTT 
assay with uridine, tri-esterified derivatives and acetonide. 
The uridine and its derivatives, to the lower concentrations 
evaluated, did not present significant inhibition on cell vi-
ability in CHO-K1 and MCF-7 cells (1 µM and 10 µM), a 
reduction in the cell viability was observed on both lines, 
when the nucleoside and derivatives were assessed to the 
maximum concentration (100 µM). However, only three 
derivatives (acetonide and compounds 2 and 3) showed 
significant inhibition on cellular viabilities of CHO-K1 cell 
line (99, 80, 30%, respectively) and MCF-7 cell line (90, 30, 
30%, respectively). The uridine to the highest concentration 
tested (100 µM), diminished the cell viability of MCF-7 cells 
around 20% compared.
 
Figure 2. Cell viability of triesterified derivatives (C1-C4, 
assessed compounds) with 1μM, 10μM and 100μM concen-
trations during 48 hours. A. CHO-K1 cell line. B. MCF-7 cell 
line. C- (Control without treatment), Urd: Uridine, and Csint: 
uridine acetonide. Data are shown as mean± S.D. Statistic 
significance was calculated with p<0.05.
DISCUSSION
Chemical
The low yields for tri-acyl ester derivatives possibly are 
due to three reasons: The first, the Steglich esterification re-
quires the formation of O-acyl-isourea intermediate, start-
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ing of N,N’-dicyclohexyl-carbodiimide and the carboxylic 
acid, this intermediate presents a reactivity similar to the 
corresponding carboxylic anhydride, however, the fatty O-
acyl-isourea intermediate is a bulky compound, the steric 
effects cause a decrease of effective shocks between the 
intermediate and nucleophilic catalyst (DMAP), therefore 
the reaction rate and yields are low14,17,18. The aromatic O-
acyl-isourea intermediate is weakly activated, this showed 
less reactivity and higher stability, due to the π-density de-
localization between aromatic and carbonyl system. There-
fore, alone a uridine derivative with aromatic acids was 
obtained17.
Another reason is due the steric effects presented in the 
uridine, between the aromatic or fatty acyl ester groups 
(adjacent to hydroxyl) and acyl group of quaternary amide 
intermediate (intermediate formed by reaction among O-
acyl-isourea and DMAP), when the hydroxyl is approaches 
to carbonyl of intermediate14,17,19. Finally, in the reactions 
carried out with a solvents mix of mean polarity, these sol-
vents prevents that substrate dissolves completely in the 
organic phase, therefore the effective collisions between 
the substrate and intermediate 2 are decreased (quaternary 
acyl amide).
The COSY H-H spectrum for 3’,4’,6’-O-trimyristoil-uridine 
in CDCl3 presents a coupling by multiple of H-5’ and H-6’ 
protons of ribose and a multiplet with high deshielding, 
δ5.36 ppm appears for H-3’ and H-4’ protons of ribose 
(they protons are overlapped), at the same time, this mul-
tiple is coupled with a highly deshielded doublet, δ=6.08 
ppm appears for the H-2’ proton (the anomeric proton). 
However, the H-3’ and the H-4’ protons of the ribose in the 
spectrum for 3’,4’,6’-O-trimyristoyl-uridine in DMSO d-6, 
are not overlapped (see table 1 and figure 1). In down-field 
is observed a coupling by the doublet δ=5.80 ppm appears 
for the H-5 proton of uracil and the doublet with highest 
deshielding δ=7.45 ppm, appears for the H-6 proton of ura-
cil (see table 1).
The HSQC spectrum for 3’,4’,6’-O-trimyristoyl-uridine 
in CDCl3, presents two couplings by the multiplet of the 
H-5’ and H-6’ protons of ribose with two kinds of carbons: 
a highly shielding carbon, δ=62.61 ppm, appears for the 
C-6’ (-CH2-) carbon of ribose and another carbon with high 
deshielding δ=80.18 ppm, appear for the C-5’ (-CH-) carbon 
of ribose. Besides, it is observed other two couplings be-
tween the multiplete of the H-3’ and H-4’ protons of ribose 
and two signals of carbons: a carbon with chemical shift 
δ=70.05 ppm, appears for the C-4’ carbon of ribose and oth-
er carbon with higher deshielding (δ=72.61 ppm) appears 
for the C-3’ carbon of ribose (see table 1). Furthermore, this 
showed a coupling by the anomeric proton (position H-2’ 
of ribose) with a carbon high deshielding, δ=87.17 ppm 
appear for the C-2’ carbon of ribose. In down-field, is ob-
served a coupling by doublet for H-5 proton of uracil and 
a carbon with high deshielding δ=103.16 ppm, carbon of 
the same position. Finally, the spectrum presents a coupling 
between the proton with highest deshielding (position H-6 
of uracil) and a highly deshielded carbon, δ=139.12 ppm, 
appears for the C-6 carbon of uracil (see table 1). Similarly 
the other compounds were analyzed.
The HMBC spectrum for 3’,4’,6’-O-trimyristoyl-uridine in 
CDCl3, presents a coupling by multiplete of H-3’ and H-4’ 
protons of ribose and a signal from highly deshielded qua-
ternary carbons, δ=172.46 ppm appear for the ester carbon-
yls. Other similary coupling is observed that the multiplet 
for the H-6’ proton of ribose and the highest deshielding 
quaternary carbon, δ=174.11 ppm appears for a ester car-
bonyl (see table 1). In down-field, the spectrum presents 
two coupling between the doublet for the H-5 proton of 
uracil and two kinds carbon, a highly shielding carbon, 
δ=139.12 ppm appear for C-6 carbon of uracil, and other 
carbon with high deshielding, δ=157.18 ppm appears for 
the C-4 carbon of uracil (carbonyl of amide type of a α,β-
unsaturated carbonyl system). Finally, two coupling is ob-
served by the proton with highest deshielding (H-6 proton 
of uracil) is coupled with two kinds carbon, a carbon with 
high shielding, δ=103.16 ppm appear for C-5 carbon of ura-
cil and other carbon with higher deshielding, δ=157.18 ppm 
appear for the C-4 amide carbonyl type (see table 1). Simi-
larly the other compounds were analyzed.
Viability assay
The cytotoxic activity results (No significant effect on cell 
viability) obtained by uridine and derivatives, possibly 
indicate a resistance to the nucleoside for the MCF-7 cell 
line. Possibly due, first, the enzymatic targets (pyr1-3 and 
pyr5,6) may present a overproduction, these generally 
participate in the novo synthesis of pyrimidine nucleo-
sides, the enzymatic overproduction nullifies the nucleo-
side savage route20. Second, the transmembrane transport 
channels of nucleosides (phosphoglycoprotein) can to be 
overexpressed, this process can cause a reduction in the nu-
cleoside incorporation since exterior of cell21. And third, the 
overexpression of receptors of tyrosine kinase (ErbB) can 
accelerate of the cell cycle and deactivate the stop of cell 
cycle performed by nucleosides2.
The nucleoside acetonide and derivatives 2 (3’,4’,6’-o-tris-
(o-n-acetyl)-benzoyl-uridine) and 3 (3’,4’,6’-o-trimyristoyl-
uridine) showed higher inhibition effect on viability of 
MCF-7 cell line than uridine, this could to be due to best 
permeability across the cell membrane, provided by sub-
stitutes and lower stability among esterase enzymes than 
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the other derivatives, due to a little higher repulsion among 
adjacent chains, therefore, the hydrolysis of 6’-acyl ester 
groups can to be viable and thermodynamically favorable, 
and it is allowed posterior phosphorylation of the OH-6’ 
hydroxyl group9,17,19. No similar behavior for the compound 
1 (3’,4’,6’-o-triacetyl-uridine) and compound 4 (3’,4’,6’-tris-
tearoyl-uridine) was observed, possibly due that the first, 
can to be more labile and easily degraded, and the second, 
maybe presents a great steric impediment and high stabil-
ity among esterase enzymes9,17,19.
CONCLUSIONS
Steglich esterification method allowed obtaining uridine 
tri-esterified derivatives. The three hydroxyl groups esteri-
fication, was possible due that the OH-3’ and OH-4’ posi-
tion are syn among themselves, and anti respect to the ura-
cil ring and other hydroxyl group (position 6’), therefore, 
aliphatic chains move away like scissor. Steglich esterifica-
tion method using aromatic acids, showed low efficiency 
possibly due to a great stability exhibited by the O-acyl-
isourea intermediate.
No significant effect on cell viability for the uridine and 
derivatives was observed with p<0.05, these substances 
did not present a dose-response relationship. However, the 
compound 3’,4’-uridine acetonide, showed a differential ef-
fect and a higher activity over cell viability on MCF-7 hu-
man cancer breast cell line than for the CHO-K1 cell line. 
Breast cancer cell line MCF-7 employed, according to re-
sults, possibly presented resistance to uridine nucleoside.
Some of the uridine derivatives, particularly with fatty ac-
ids are too bulky, this property can inhibit the hydrolysis of 
6’-acyl-ester gruop of the ribose and produce decreassed of 
phosphorylation (activation) of the nucleoside.
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